Search research articles
Contact Us
Filters
Showing results (611-620 of 625) with videos related to
Page
of 63
Sort By:
Journal of Medicinal Chemistry
|
August 15, 2022
Identification of Monosaccharide Derivatives as Potent, Selective, and Orally Bioavailable Inhibitors of Human and Mouse Galectin-3
Chunjian Liu, Prasada Rao Jalagam, Jianxin Feng, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 9, 2023
Discovery of novel pyridinones as MGAT2 inhibitors for the treatment of metabolic disorders
Fang Moore, Wei Wang, Guohua Zhao, et al.
World Journal of Gastroenterology
|
June 20, 2025
Evaluating log odds of positive lymph nodes as a prognostic tool in differentiated gastric cancer: A retrospective study
Ming-Cong Deng, Ken Chen, Qi-Mei Bao, et al.
Cell Metabolism
|
November 2, 2022
MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity
Dong Cheng, Bradley A Zinker, Yi Luo, et al.
Communications Medicine
|
October 25, 2023
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients
Junichiro Yuda, Christine Will, Darren C Phillips, et al.
Cancer Research
|
March 25, 2018
A Large-Scale, Exome-Wide Association Study of Han Chinese Women Identifies Three Novel Loci Predisposing to Breast Cancer
Bo Zhang, Men-Yun Chen, Yu-Jun Shen, et al.
Journal of Medicinal Chemistry
|
September 19, 2023
Discovery of <b>12</b> (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders
Wei Meng, Robert Brigance, James Mignone, et al.
Molecular Cancer Therapeutics
|
May 5, 2017
Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors
Julie L Wilsbacher, Min Cheng, Dong Cheng, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 15, 2017
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT)
Michael L Curtin, H Robin Heyman, Richard F Clark, et al.
Journal of Medicinal Chemistry
|
October 6, 2021
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders
Huji Turdi, Hannguang Chao, Jon J Hangeland, et al.
Page
of 63
Search research articles
Search
Showing results (611-620 of 625) with videos related to
Sort By:
Page
of 63
Journal of Medicinal Chemistry
|
August 15, 2022
Identification of Monosaccharide Derivatives as Potent, Selective, and Orally Bioavailable Inhibitors of Human and Mouse Galectin-3
Chunjian Liu, Prasada Rao Jalagam, Jianxin Feng, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 9, 2023
Discovery of novel pyridinones as MGAT2 inhibitors for the treatment of metabolic disorders
Fang Moore, Wei Wang, Guohua Zhao, et al.
World Journal of Gastroenterology
|
June 20, 2025
Evaluating log odds of positive lymph nodes as a prognostic tool in differentiated gastric cancer: A retrospective study
Ming-Cong Deng, Ken Chen, Qi-Mei Bao, et al.
Cell Metabolism
|
November 2, 2022
MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity
Dong Cheng, Bradley A Zinker, Yi Luo, et al.
Communications Medicine
|
October 25, 2023
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients
Junichiro Yuda, Christine Will, Darren C Phillips, et al.
Cancer Research
|
March 25, 2018
A Large-Scale, Exome-Wide Association Study of Han Chinese Women Identifies Three Novel Loci Predisposing to Breast Cancer
Bo Zhang, Men-Yun Chen, Yu-Jun Shen, et al.
Journal of Medicinal Chemistry
|
September 19, 2023
Discovery of <b>12</b> (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders
Wei Meng, Robert Brigance, James Mignone, et al.
Molecular Cancer Therapeutics
|
May 5, 2017
Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors
Julie L Wilsbacher, Min Cheng, Dong Cheng, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 15, 2017
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT)
Michael L Curtin, H Robin Heyman, Richard F Clark, et al.
Journal of Medicinal Chemistry
|
October 6, 2021
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders
Huji Turdi, Hannguang Chao, Jon J Hangeland, et al.
Page
of 63